ReviewFrontiers in pharmacology2025
Post stroke depression: pathogenesis and molecular mechanisms of natural product-based interventions.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness and safety of hyperbaric oxygen therapy for psychiatric disorders: A systematic review and meta-analysis.Psychiatry and clinical neurosciences · 2026Pooled it
- Effects of noninvasive brain stimulation in the treatment of poststroke depression: an overview of systematic reviews.Frontiers in neurologyPooled it
- Effectiveness of non-pharmacological interventions for post-stroke depression: protocol for an umbrella review of systematic reviews and meta-analyses.Systematic reviews · 2026Article
- Basic and clinical research on acupuncture for post-stroke depression: A narrative review.World journal of methodology · 2026Review
- Polygenic risk for depression is associated with post-stroke depression and stroke.IBRO neuroscience reports · 2026Article
- Immunotherapy for depression: targeting cytokine pathways in major depressive disorder.Psychopharmacology · 2026Review
- Stroke Survivors Have Almost Three Times Higher Risk of Depression: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Cognitive Impairment and Psychological Morbidity Among Stroke Survivors in Rehabilitation: A Cross-Sectional Analysis.Journal of clinical medicine · 2025Article
- Ketamine in post-stroke depression: a report of 2 cases.Frontiers in psychiatry · 2025Article
- Cilostazol-inhibited RhoA/NF-κB signaling mitigates hippocampal inflammation and post-stroke depression.Frontiers in pharmacology · 2025Article
- Rate of Post-Stroke Depression and Associated Factors in Saudi Single Tertiary Medical Center.Journal of multidisciplinary healthcare · 2025Article
- Research advances on the pathogenesis and clinical interventions of post-stroke depression.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke depression (PSD) is a common sequela of stroke and a neuropsychiatric disorder associated with poor recovery, significant cognitive deficits, and reduced quality of life. Many natural products (NPs), known for their diverse biological activities, low toxicity, as well as multi-targeting capabilities, offer distinct advantages in PSD treatment by modulating pathological mechanisms. However, a comprehensive summary of the pathological mechanisms of PSD and the molecular mechanisms of NPs intervention is currently lacking. This review aimed to investigate the pathological mechanisms of PSD. It also explored the pharmacological mechanisms by which NPs exerted anti-PSD effects and in-depth discussion the limitations of current studies. Furthermore, it proposed novel methodologies for future preclinical and clinical translation in PSD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.